Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment (ROLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01796288
Recruitment Status : Unknown
Verified October 2012 by FU XIAO LONG, Wu Jieping Medical Foundation.
Recruitment status was:  Recruiting
First Posted : February 21, 2013
Last Update Posted : February 21, 2013
Sponsor:
Collaborators:
Shanghai Chest Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Fudan University
Zhejiang Cancer Hospital
Anhui Provincial Hospital
Anhui Medical University
Wuxi No. 4 People's Hospital
Information provided by (Responsible Party):
FU XIAO LONG, Wu Jieping Medical Foundation

Brief Summary:
This was a multi-center randomized controlled Phase II clinical trial. Patients with oligometastatic stage IV (number of distant metastases ≤ 5) non-squamous non-small cell lung cancer treated with second-line erlotinib150mg daily for 3 months with clinical benefits (free-from progression) were randomized (stratified according to smoking status and different research centers) to the radiotherapy group (n = 100) and the non-radiotherapy group (n = 100). Radiotherapy group (experimental group) patients started simultaneously radiotherapy for all gross tumors soon after randomization; non-radiotherapy group (control group) received no radiotherapy for all gross tumors. Erlotinib was continuously used until to disease progression or unbearable adverse effect, and the subsequently further salvage therapies were determined by the investigators. The primary endpoint was PFS.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer, Oligometastatic Radiation: simultaneous radiotherapy Drug: Erlotinib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment: a Randomized Controlled Phase II Clinical Trial
Study Start Date : October 2012
Estimated Primary Completion Date : April 2016
Estimated Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Erlotinib & simultaneous radiotherapy
patients started simultaneously radiotherapy for all gross tumors
Radiation: simultaneous radiotherapy
Drug: Erlotinib
Erlotinib & no radiotherapy
patients received no radiotherapy for all gross tumors
Drug: Erlotinib



Primary Outcome Measures :
  1. progession-free survival [ Time Frame: 3.5 year ]

Secondary Outcome Measures :
  1. overall survival [ Time Frame: 5 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Has signed informed consent;
  2. Male or female aged 18 years or older;
  3. Histologically or cytologically identified non-squamous non-small cell lung cancer;
  4. PS score 0-2;
  5. Stage IV patients with distant metastasis (according to the latest AJCC/UICC lung cancer staging, upper neck lymph nodes belonging to distant metastases; ipsilateral/contralateral mediastinal lymph nodes, supraclavicular and lower neck lymph nodes belonging to local regional areas and are not included in distant metastases), who occurred disease progression after receiving a course of systemic chemotherapy, or who hadn't complete the planned course of the first-line chemotherapy but they were intolerance or refused to continue treatment;
  6. Received second-line erlotinib treatment;
  7. The patients who taking erlotinib for 3 months then the efficacy evaluation found clinical benefits (CR+PR+SD);
  8. Metastatic NSCLC with distant metastases number ≤ 5 (for metastases in the same organ, the number counted as the separate metastatic focus) and the longest diameter of each metastatic foci on CT should > 1cm, but brain (including the parenchyma and meninges) metastasis, malignant pleural/pericardial effusion, or abdominal effusion were not allowed;
  9. Have never received local treatment, including surgery, radiation therapy, and radiofrequency ablation for primary and distant metastases;
  10. Patients must received systemic PET-CT examination before treatment with erlotinib, to more accurately identify the status of patients with distant metastases;
  11. The diagnosis of bone and liver metastases:

    1. On the basis of clinical symptoms, an imaging support was necessary for the clinical diagnosis of bone metastases; if the clinical symptoms were absent, two imaging supports of bone metastases were necessary for the clinical diagnosis of bone metastasis; adjacent bone metastases (such as the two adjacent vertebral metastases) was considered to be a single metastasis.
    2. MRI or enhanced CT confirmations were needed for liver metastases diagnosis;
  12. Have never received other targeted drug treatments for EGFR inhibition;
  13. If metastases in a same organ ≤ 4 and the amount of metastatic focus ≤ 5, it should be determined by the radiation therapists in the research group to judge if the patients can tolerate all positive focus (including primary and metastatic focus) receiving radiotherapy, the radiotherapy dose should be selected by treating physician according to the patients' conditions from several regimens including conventional split curative doses or palliative doses, and hypofractionated radiotherapy (for details please refer to the radiation therapy section);
  14. Organ function levels must meet the following requirements:

    1. Bone marrow: absolute neutrophil count (ANC) ≥ 1.0 × 109/L, platelets ≥ 80 × 109/L, hemoglobin ≥ 9 g/L;
    2. Liver: serum bilirubin ≤ 1.5 times of the upper limit of normal, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times of the upper limit of normal (if liver metastases existing, ALT, AST ≤ 5 times of the upper limit of normal were allowed) ;
    3. Kidney: serum creatinine ≤ 2 times of the upper limit of normal or creatinine clearance ≥ 45mL/min;
  15. For female patients: must after natural menopause, surgical menopause, or used any medical allowed contraceptive method during treatment and within 3 months after treatment completion; serum or urine pregnancy test must be negative; mustn't be in lactation. For male patients: surgical sterilization, or took contraceptive measures during treatment and within 3 months after treatment completion.

Exclusion Criteria:

  1. The pathological type was squamous cell carcinoma, or mixed with small cell components in non-small cell lung cancer;
  2. With brain metastasis regardless of parenchymal or meningeal metastasis;
  3. Malignant pleural effusion, pericardial effusion or peritoneal effusion;
  4. The longest diameter of metastatic focus on CT were <1cm, or the amount of metastatic focus > 5;
  5. Metastases appeared within a same organ simultaneously;
  6. The efficacy evaluation after erlotinib treatment for 3 months showed PD (progression of disease);
  7. Local treatment had been used for the primary and distant metastatic focus;
  8. Radiation therapists thought that the patient couldn't tolerate/receive radiotherapy for all the focus;
  9. Has previously suffered from interstitial lung disease, drug-induced interstitial lung disease, or any active interstitial lung disease with clinical evidences;
  10. Chest CT found idiopathic pulmonary fibrosis;
  11. Patients with multiple pulmonary bullae, chronic lung disease, or acute lung infection;
  12. With any chronic toxicity induced by previous anti-cancer treatment, it was undimunished and higher than CTCAE level 2;
  13. Diagnosed or accompanied by any other malignant disease (except basal cell carcinoma or cervical carcinoma in situ) over the past five years;
  14. According to the judgments of the investigators, there was any serious or uncontrolled systemic disease (e.g. heart, liver, or kidney disease) or active infection;
  15. Combined use with phenytoin, carbamazepine, rifampicin, phenobarbital, or St. John's wort;
  16. Naïve patients who have never received chemotherapy;
  17. With previously clear history of neurological or psychiatric disorder, such as dementia;
  18. Pregnancy or lactating patients;
  19. Patients receiving other anti-tumor medicine not for this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01796288


Contacts
Layout table for location contacts
Contact: Xiaolong Fu, ph.D&MD xlfu1964@126.com

Locations
Layout table for location information
China, Shanghai
Fudan University Shanghai Cancer Center Recruiting
Shanghai, Shanghai, China, 200032
Contact: Xiaolong Fu, ph.D&MD       xlfu1964@126.com   
Principal Investigator: Xiaolong Fu, ph.D&MD         
Sponsors and Collaborators
Wu Jieping Medical Foundation
Shanghai Chest Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Fudan University
Zhejiang Cancer Hospital
Anhui Provincial Hospital
Anhui Medical University
Wuxi No. 4 People's Hospital

Layout table for additonal information
Responsible Party: FU XIAO LONG, Fudan University Shanghai Cancer Center, Wu Jieping Medical Foundation
ClinicalTrials.gov Identifier: NCT01796288     History of Changes
Other Study ID Numbers: 1209114-5
First Posted: February 21, 2013    Key Record Dates
Last Update Posted: February 21, 2013
Last Verified: October 2012

Keywords provided by FU XIAO LONG, Wu Jieping Medical Foundation:
NSCLC
oligometastatic
second-line
Radiotherapy
Erlotinib

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action